Gulick Roy M
Division of International Medicine and Infectious Diseases, Weill Medical College of Cornell University, New York, NY 10021, USA.
Infect Dis Clin North Am. 2007 Mar;21(1):71-84, viii. doi: 10.1016/j.idc.2007.01.002.
Antiretroviral management of treatment-naive patients begins with the decision of when to start treatment. Current treatment guidelines suggest starting therapy in anyone with AIDS, HIV-related symptoms, or a CD4 cell count less than 200/mm3 regardless of symptoms. Starting treatment in asymptomatic patients with CD4 of more than 200 requires consideration of a number of pros and cons, and individualization is the key. Recommended first-line antiretroviral regimens consist of two nucleoside reverse transcriptase inhibitors together with either a nonnucleoside reverse transcriptase inhibitor or a protease inhibitor (with or without ritonavir boosting). The goal of antiretroviral therapy is maximally to suppress viremia, enhance or improve immune function, and prevent clinical progression.